论文部分内容阅读
探讨血浆中可溶性 CD44标准型、v6和 v7- v8变构体的表达水平与四类肺癌的发生和转移的关系。方法 :用我们自己建立的通用免疫杂交法定量测定 5 9例肺癌患者血浆 s CD44 S、s CD44 v6、s CD44 v7- v8的含量。结果 :原发性肺癌 (5 2例 )和转移性肺癌 (7例 )的 s CD44 v6表达水平明显高于正常对照组 (P<0 .0 0 1)和肺慢性炎症对照组 (P<0 .0 5 ) ;原发性未转移组 (2 2例 )与原发性转移组 (30例 )比较 ,差异不显著 (P>0 .0 5 )。未转移组鳞癌的 s CD44 S检测水平低于正常水平 (P<0 .0 5 ) ,与肺泡癌比较差异有显著性 (P<0 .0 5 )。四类肺癌组 s CD44 v6均极显著高于正常组 ,肺泡癌与小细胞癌比较差异有显著性 (P<0 .0 5 )。s CD44 v7- v8在肺癌中无特别意义。结论 :s CD44 v6与肺癌的恶性增殖和转移密切相关 ,s CD44 v6可作为肺癌的早期诊断 ,疗效评价 ,转移和复发的监测指标。
To investigate the relationship between plasma soluble CD44, v6 and v7-v8 variants and the occurrence and metastasis of four types of lung cancer. METHODS: The plasma levels of sCD44 S, s CD44 v6 and s CD44 v7-v8 in 59 patients with lung cancer were assayed by our own universal immunoblot assay. Results: The expressions of CD44 v6 in primary lung cancer (52 cases) and metastatic lung cancer (7 cases) were significantly higher than those in normal control group (P <0.01 01) and chronic lung inflammation group (P <0 .0 5). There was no significant difference between primary metastasis group (22 cases) and primary metastasis group (30 cases) (P> 0.05). The level of CD44 S in non-metastatic squamous cell carcinoma was lower than normal (P <0.05), which was significantly different from that of alveolar carcinoma (P <0.05). The sCD44v6 in the four groups of lung cancer was significantly higher than that in the normal group, and there was significant difference between small cell lung cancer and small cell lung cancer (P <0.05). s CD44 v7- v8 has no special significance in lung cancer. Conclusion: CD44 v6 is closely related to the malignant proliferation and metastasis of lung cancer. CD44 v6 can be used as an indicator of early diagnosis, evaluation, metastasis and recurrence of lung cancer.